logo
  

Asensus Surgical Agrees To Karl Storz's Acquisition Offer; Stock Up

Asensus Surgical, Inc. (ASXC) announced on Wednesday that it has entered into a non-binding letter of intent with medical technology company Karl Storz SE & Co. KG regarding the company's potential acquisition at a purchase price of $0.35 per share in cash.

Under the agreement, Asensus would not engage in acquisition negotiations with any other party for a period of up to ten weeks, during which a merger agreement with Karl Storz is expected to be finalized.

The medical device company said that it would receive a bridge loan of $20 million from Karl Storz to meet immediate financial obligations during the exclusivity period.

Asensus also stated that it has formed a transaction committee of the Board of Directors to consider the terms of the merger agreement.

Currently, Asensus's stock is gaining 29.80 percent, to $0.277 on the New York Stock Exchange.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
AbbVie (ABBV) Monday announced a collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals, a clinical stage neuroscience biotech firm, to develop next-generation treatment approaches and unmet needs in psychiatric disorders. AbbVie noted that the first-generation compounds may... Healthwest Minerals, Inc. d/b/a Mt. Capra Products has recalled 1,506 boxes of Goat Milk Formula Recipe Kit, also urging consumers to immediately discontinue use of the product as infant formula. The firm does not recommend using this product for infants from 0-12 months of age. Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
RELATED NEWS
Follow RTT